TP53 and B-cell chronic lymphocytic leukemia: Also, in the era of novel target agents, TP53 abn remains a negative predictive marker for CLL and is associated with worse PFS and OS, especially for those cases harboring both 17p- and TP53 mutations [71,72,73,74].